SIRPA-Inhibited, Marrow-Derived Macrophages Engorge, Accumulate, and Differentiate in Antibody-Targeted Regression of Solid Tumors

Cory M. Alvey, Kyle R. Spinler, Jerome Irianto, Charlotte R. Pfeifer, Brandon Hayes, Yuntao Xia, Sangkyun Cho, P. C.P.Dave Dingal, Jake Hsu, Lucas Smith, Manu Tewari, Dennis E. Discher

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Marrow-derived macrophages are highly phagocytic, but whether they can also traffic into solid tumors and engulf cancer cells is questionable, given the well-known limitations of tumor-associated macrophages (TAMs). Here, SIRPα on macrophages from mouse and human marrow was inhibited to block recognition of its ligand, the “marker of self” CD47 on all other cells. These macrophages were then systemically injected into mice with fluorescent human tumors that had been antibody targeted. Within days, the tumors regressed, and single-cell fluorescence analyses showed that the more the macrophages engulfed, the more they accumulated within regressing tumors. Human-marrow-derived macrophages engorged on the human tumors, while TAMs were minimally phagocytic, even toward CD47-knockdown tumors. Past studies had opsonized tumors in situ with antibody and/or relied on mouse TAMs but had not injected SIRPα-inhibited cells; also, unlike past injections of anti-CD47, blood parameters remained normal and safe. Consistent with tumor-selective engorge-and-accumulate processes in vivo, phagocytosis in vitro inhibited macrophage migration through micropores that mimic features of dense 3D tissue. Accumulation of SIRPα-inhibited macrophages in tumors favored tumor regression for 1–2 weeks, but donor macrophages quickly differentiated toward non-phagocytic, high-SIRPα TAMs. Analyses of macrophages on soft (like marrow) or stiff (like solid tumors) collagenous gels demonstrated a stiffness-driven, retinoic-acid-modulated upregulation of SIRPα and the mechanosensitive nuclear marker lamin-A. Mechanosensitive differentiation was similarly evident in vivo and likely limited the anti-tumor effects, as confirmed by re-initiation of tumor regression by fresh injections of SIRPα-inhibited macrophages. Macrophage motility, phagocytosis, and differentiation in vivo are thus coupled.

Original languageEnglish (US)
Pages (from-to)2065-2077.e6
JournalCurrent Biology
Volume27
Issue number14
DOIs
StatePublished - Jul 24 2017
Externally publishedYes

Fingerprint

Macrophages
Tumors
macrophages
Bone Marrow
neoplasms
antibodies
Antibodies
Neoplasms
remission
phagocytosis
mice
Phagocytosis
injection
micropores
Lamin Type A
Single-Cell Analysis
retinoic acid
cells
Injections
traffic

Keywords

  • immunotherapy
  • lamins
  • mechanobiology
  • motility
  • phagocytosis

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Alvey, C. M., Spinler, K. R., Irianto, J., Pfeifer, C. R., Hayes, B., Xia, Y., ... Discher, D. E. (2017). SIRPA-Inhibited, Marrow-Derived Macrophages Engorge, Accumulate, and Differentiate in Antibody-Targeted Regression of Solid Tumors. Current Biology, 27(14), 2065-2077.e6. https://doi.org/10.1016/j.cub.2017.06.005

SIRPA-Inhibited, Marrow-Derived Macrophages Engorge, Accumulate, and Differentiate in Antibody-Targeted Regression of Solid Tumors. / Alvey, Cory M.; Spinler, Kyle R.; Irianto, Jerome; Pfeifer, Charlotte R.; Hayes, Brandon; Xia, Yuntao; Cho, Sangkyun; Dingal, P. C.P.Dave; Hsu, Jake; Smith, Lucas; Tewari, Manu; Discher, Dennis E.

In: Current Biology, Vol. 27, No. 14, 24.07.2017, p. 2065-2077.e6.

Research output: Contribution to journalArticle

Alvey, CM, Spinler, KR, Irianto, J, Pfeifer, CR, Hayes, B, Xia, Y, Cho, S, Dingal, PCPD, Hsu, J, Smith, L, Tewari, M & Discher, DE 2017, 'SIRPA-Inhibited, Marrow-Derived Macrophages Engorge, Accumulate, and Differentiate in Antibody-Targeted Regression of Solid Tumors', Current Biology, vol. 27, no. 14, pp. 2065-2077.e6. https://doi.org/10.1016/j.cub.2017.06.005
Alvey, Cory M. ; Spinler, Kyle R. ; Irianto, Jerome ; Pfeifer, Charlotte R. ; Hayes, Brandon ; Xia, Yuntao ; Cho, Sangkyun ; Dingal, P. C.P.Dave ; Hsu, Jake ; Smith, Lucas ; Tewari, Manu ; Discher, Dennis E. / SIRPA-Inhibited, Marrow-Derived Macrophages Engorge, Accumulate, and Differentiate in Antibody-Targeted Regression of Solid Tumors. In: Current Biology. 2017 ; Vol. 27, No. 14. pp. 2065-2077.e6.
@article{588150d57f87415fa58f3ced68ecaf22,
title = "SIRPA-Inhibited, Marrow-Derived Macrophages Engorge, Accumulate, and Differentiate in Antibody-Targeted Regression of Solid Tumors",
abstract = "Marrow-derived macrophages are highly phagocytic, but whether they can also traffic into solid tumors and engulf cancer cells is questionable, given the well-known limitations of tumor-associated macrophages (TAMs). Here, SIRPα on macrophages from mouse and human marrow was inhibited to block recognition of its ligand, the “marker of self” CD47 on all other cells. These macrophages were then systemically injected into mice with fluorescent human tumors that had been antibody targeted. Within days, the tumors regressed, and single-cell fluorescence analyses showed that the more the macrophages engulfed, the more they accumulated within regressing tumors. Human-marrow-derived macrophages engorged on the human tumors, while TAMs were minimally phagocytic, even toward CD47-knockdown tumors. Past studies had opsonized tumors in situ with antibody and/or relied on mouse TAMs but had not injected SIRPα-inhibited cells; also, unlike past injections of anti-CD47, blood parameters remained normal and safe. Consistent with tumor-selective engorge-and-accumulate processes in vivo, phagocytosis in vitro inhibited macrophage migration through micropores that mimic features of dense 3D tissue. Accumulation of SIRPα-inhibited macrophages in tumors favored tumor regression for 1–2 weeks, but donor macrophages quickly differentiated toward non-phagocytic, high-SIRPα TAMs. Analyses of macrophages on soft (like marrow) or stiff (like solid tumors) collagenous gels demonstrated a stiffness-driven, retinoic-acid-modulated upregulation of SIRPα and the mechanosensitive nuclear marker lamin-A. Mechanosensitive differentiation was similarly evident in vivo and likely limited the anti-tumor effects, as confirmed by re-initiation of tumor regression by fresh injections of SIRPα-inhibited macrophages. Macrophage motility, phagocytosis, and differentiation in vivo are thus coupled.",
keywords = "immunotherapy, lamins, mechanobiology, motility, phagocytosis",
author = "Alvey, {Cory M.} and Spinler, {Kyle R.} and Jerome Irianto and Pfeifer, {Charlotte R.} and Brandon Hayes and Yuntao Xia and Sangkyun Cho and Dingal, {P. C.P.Dave} and Jake Hsu and Lucas Smith and Manu Tewari and Discher, {Dennis E.}",
year = "2017",
month = "7",
day = "24",
doi = "10.1016/j.cub.2017.06.005",
language = "English (US)",
volume = "27",
pages = "2065--2077.e6",
journal = "Current Biology",
issn = "0960-9822",
publisher = "Cell Press",
number = "14",

}

TY - JOUR

T1 - SIRPA-Inhibited, Marrow-Derived Macrophages Engorge, Accumulate, and Differentiate in Antibody-Targeted Regression of Solid Tumors

AU - Alvey, Cory M.

AU - Spinler, Kyle R.

AU - Irianto, Jerome

AU - Pfeifer, Charlotte R.

AU - Hayes, Brandon

AU - Xia, Yuntao

AU - Cho, Sangkyun

AU - Dingal, P. C.P.Dave

AU - Hsu, Jake

AU - Smith, Lucas

AU - Tewari, Manu

AU - Discher, Dennis E.

PY - 2017/7/24

Y1 - 2017/7/24

N2 - Marrow-derived macrophages are highly phagocytic, but whether they can also traffic into solid tumors and engulf cancer cells is questionable, given the well-known limitations of tumor-associated macrophages (TAMs). Here, SIRPα on macrophages from mouse and human marrow was inhibited to block recognition of its ligand, the “marker of self” CD47 on all other cells. These macrophages were then systemically injected into mice with fluorescent human tumors that had been antibody targeted. Within days, the tumors regressed, and single-cell fluorescence analyses showed that the more the macrophages engulfed, the more they accumulated within regressing tumors. Human-marrow-derived macrophages engorged on the human tumors, while TAMs were minimally phagocytic, even toward CD47-knockdown tumors. Past studies had opsonized tumors in situ with antibody and/or relied on mouse TAMs but had not injected SIRPα-inhibited cells; also, unlike past injections of anti-CD47, blood parameters remained normal and safe. Consistent with tumor-selective engorge-and-accumulate processes in vivo, phagocytosis in vitro inhibited macrophage migration through micropores that mimic features of dense 3D tissue. Accumulation of SIRPα-inhibited macrophages in tumors favored tumor regression for 1–2 weeks, but donor macrophages quickly differentiated toward non-phagocytic, high-SIRPα TAMs. Analyses of macrophages on soft (like marrow) or stiff (like solid tumors) collagenous gels demonstrated a stiffness-driven, retinoic-acid-modulated upregulation of SIRPα and the mechanosensitive nuclear marker lamin-A. Mechanosensitive differentiation was similarly evident in vivo and likely limited the anti-tumor effects, as confirmed by re-initiation of tumor regression by fresh injections of SIRPα-inhibited macrophages. Macrophage motility, phagocytosis, and differentiation in vivo are thus coupled.

AB - Marrow-derived macrophages are highly phagocytic, but whether they can also traffic into solid tumors and engulf cancer cells is questionable, given the well-known limitations of tumor-associated macrophages (TAMs). Here, SIRPα on macrophages from mouse and human marrow was inhibited to block recognition of its ligand, the “marker of self” CD47 on all other cells. These macrophages were then systemically injected into mice with fluorescent human tumors that had been antibody targeted. Within days, the tumors regressed, and single-cell fluorescence analyses showed that the more the macrophages engulfed, the more they accumulated within regressing tumors. Human-marrow-derived macrophages engorged on the human tumors, while TAMs were minimally phagocytic, even toward CD47-knockdown tumors. Past studies had opsonized tumors in situ with antibody and/or relied on mouse TAMs but had not injected SIRPα-inhibited cells; also, unlike past injections of anti-CD47, blood parameters remained normal and safe. Consistent with tumor-selective engorge-and-accumulate processes in vivo, phagocytosis in vitro inhibited macrophage migration through micropores that mimic features of dense 3D tissue. Accumulation of SIRPα-inhibited macrophages in tumors favored tumor regression for 1–2 weeks, but donor macrophages quickly differentiated toward non-phagocytic, high-SIRPα TAMs. Analyses of macrophages on soft (like marrow) or stiff (like solid tumors) collagenous gels demonstrated a stiffness-driven, retinoic-acid-modulated upregulation of SIRPα and the mechanosensitive nuclear marker lamin-A. Mechanosensitive differentiation was similarly evident in vivo and likely limited the anti-tumor effects, as confirmed by re-initiation of tumor regression by fresh injections of SIRPα-inhibited macrophages. Macrophage motility, phagocytosis, and differentiation in vivo are thus coupled.

KW - immunotherapy

KW - lamins

KW - mechanobiology

KW - motility

KW - phagocytosis

UR - http://www.scopus.com/inward/record.url?scp=85021327361&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021327361&partnerID=8YFLogxK

U2 - 10.1016/j.cub.2017.06.005

DO - 10.1016/j.cub.2017.06.005

M3 - Article

C2 - 28669759

AN - SCOPUS:85021327361

VL - 27

SP - 2065-2077.e6

JO - Current Biology

JF - Current Biology

SN - 0960-9822

IS - 14

ER -